Hikma Pharmaceuticals Regulatory News (HIK)

Hikma Pharmaceuticals PLC - Share Transactions

LONDON, 4 November 2010: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK), in accordance with DTR 3.1.2R and s.793 of the Companies Act 2006, announces that Mr. Said Darwazah, a Director and Person Discharging Managerial Responsibility has undertaken transactions in the Company's Ordinary Shares of 10p each. The transactions took place in London as detailed below.

On 2 - 3 November 2010, Mr Darwazah disposed of 300,000 Ordinary Shares of 10p each, representing 0.15 per cent. of the issued share capital of the Company, at an average price of 778.63 pence per Ordinary Share. The primary purpose of this disposal is to fund the establishment of the Samih Darwazah Center for Innovation Management and Entrepreneurship at the American University of Beirut in Lebanon.

On 4 November 2010, Mr Darwazah exercised 100,000 nil cost options, representing 0.05 per cent. of the issued share capital of the Company, granted to him under the Hikma Pharmaceuticals Long Term Incentive Plan 2005 (LTIP). Mr. Darwazah has retained all of the shares from the exercise of his LTIP.

The Company was notified of both transactions on 4 November 2010.

Following these transactions Mr. Darwazah holds 473,445 ordinary shares, representing 0.25 per cent. of the issued share capital of the Company.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC

Henry Knowles +44 20 7399 2760

Company Secretary

Susan Ringdal +44 20 7399 2760

Investor Relations Director

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2009, Hikma achieved revenues of $637 million and profit attributable to shareholders of $78 million. For news and other information, please visit www.hikma.com.